Investments
214Portfolio Exits
53Funds
9Service Providers
1About New Leaf Venture Partners
New Leaf Venture Partners is a leader in healthcare technology venture investing. They focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.
Want to inform investors similar to New Leaf Venture Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing New Leaf Venture Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find New Leaf Venture Partners in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing New Leaf Venture Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned New Leaf Venture Partners in 2 CB Insights research briefs, most recently on Feb 16, 2021.
Latest New Leaf Venture Partners News
Sep 5, 2023
Star Therapeutics , a South San Francisco, CA-based biotechnology company advancing antibody therapies, raised $90M in Series C funding. The round was led by Sofinnova Investments, and included new investors Qatar Investment Authority (QIA), Catalio Capital Management, Agent Capital, Soleus Capital, and NYBC Ventures, as well as participation from all existing investors including Westlake Village BioPartners, OrbiMed, Redmile Group, RA Capital Management, New Leaf Venture Partners, Cormorant Asset Management, and Cowen Healthcare Investments. Including this Series C round, Star Therapeutics has raised over $190m since inception to create numerous portfolio companies. The company intends to use the funds for clinical advancement of VGA039, a first-in-class antibody currently being evaluated in a Phase 1a/1b study for von Willebrand disease. This novel therapy is being developed by Vega Therapeutics, a Star portfolio company focused on underserved blood disorders. Proceeds will also be used to continue Star’s approach as an innovation engine to generate additional biotech companies focused on discovering and advancing novel antibody therapies, each targeting multiple diseases. Led by CEO Adam Rosenthal, Star Therapeutics is a biotechnology company that interrogates areas of novel biology to develop life-changing therapies for as many patients as possible, initially addressing needs in hematology and immunology. Its engine starts with identifying multiple diseases that share a common biology and then discovering novel therapeutics that can treat numerous diseases with a single therapy. Star consists of a constellation of companies, each focused on a specific area of biology with therapies. Concurrent with this financing, the Board will consist of Beth Seidenberg, MD, Founding Managing Director at Westlake Village BioPartners; Carl Gordon, PhD, Managing Partner at OrbiMed; Amrit Nagpal, Managing Director at Redmile Group, Maha Katabi, PhD, General Partner at Sofinnova Investments; Nancy Stagliano, PhD, Executive Board Chair; and Adam Rosenthal, PhD, CEO and Founder of Star. Star’s Board observers include Vijay Lathi, Founding Managing Director at New Leaf Venture Partners and Matt Hammond, PhD, Principal at RA Capital Management. FinSMEs 05/09/2023
New Leaf Venture Partners Investments
214 Investments
New Leaf Venture Partners has made 214 investments. Their latest investment was in Star Therapeutics as part of their Series C on September 9, 2023.
New Leaf Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/5/2023 | Series C | Star Therapeutics | $90M | No | Agent Capital, Catalio Capital Management, Cormorant Asset Management, Cowen Healthcare Investments, New Leaf Venture Partners, NYBC Ventures, OrbiMed Advisors, Qatar Investment Authority, RA Capital Management, Redmile Group, Sofinnova Ventures, Soleus Capital Management, and Westlake Village BioPartners | 2 |
11/9/2022 | Series B | CuraSen Therapeutics | $15M | No | 1 | |
7/26/2022 | Series B | Arine | Yes | 2 | ||
7/25/2022 | Series C | |||||
3/14/2022 | Series B - II |
Date | 9/5/2023 | 11/9/2022 | 7/26/2022 | 7/25/2022 | 3/14/2022 |
|---|---|---|---|---|---|
Round | Series C | Series B | Series B | Series C | Series B - II |
Company | Star Therapeutics | CuraSen Therapeutics | Arine | ||
Amount | $90M | $15M | |||
New? | No | No | Yes | ||
Co-Investors | Agent Capital, Catalio Capital Management, Cormorant Asset Management, Cowen Healthcare Investments, New Leaf Venture Partners, NYBC Ventures, OrbiMed Advisors, Qatar Investment Authority, RA Capital Management, Redmile Group, Sofinnova Ventures, Soleus Capital Management, and Westlake Village BioPartners | ||||
Sources | 2 | 1 | 2 |
New Leaf Venture Partners Portfolio Exits
53 Portfolio Exits
New Leaf Venture Partners has 53 portfolio exits. Their latest portfolio exit was Bellus Health on June 28, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
6/28/2023 | Acq - P2P | 6 | |||
1/20/2023 | Acq - P2P | 3 | |||
8/19/2022 | Reverse Merger | 4 | |||
Date | 6/28/2023 | 1/20/2023 | 8/19/2022 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acq - P2P | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 6 | 3 | 4 |
New Leaf Venture Partners Fund History
9 Fund Histories
New Leaf Venture Partners has 9 funds, including New Leaf Ventures III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/31/2015 | New Leaf Ventures III | Multi-Stage Venture Capital | Closed | 2 | |
6/22/2015 | New Leaf Growth Fund I | ||||
10/23/2007 | New Leaf Ventures II | ||||
8/5/2005 | New Leaf Ventures I LP | ||||
12/31/2000 | Sprout Capital IX LP |
Closing Date | 12/31/2015 | 6/22/2015 | 10/23/2007 | 8/5/2005 | 12/31/2000 |
|---|---|---|---|---|---|
Fund | New Leaf Ventures III | New Leaf Growth Fund I | New Leaf Ventures II | New Leaf Ventures I LP | Sprout Capital IX LP |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | |||||
Sources | 2 |
New Leaf Venture Partners Service Providers
1 Service Provider
New Leaf Venture Partners has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type |
Partnership data by VentureSource
New Leaf Venture Partners Team
13 Team Members
New Leaf Venture Partners has 13 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Philippe Chambon | Founder | Current | |
Name | Philippe Chambon | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
